{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-038131","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.909804+00:00","generated_at":"2026-06-15T06:12:00.097965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OptimizeRx Q1 revenue down 5% to $13.0M; GAAP EPS loss $(0.37), non-GAAP loss $(0.09)","bullets":["Total revenue $13.0M, down 5% from $13.7M a year ago; gross profit $7.4M (-8% YoY).","GAAP net loss $(6.4)M or $(0.37) per share vs. $(3.8)M or $(0.21) last year.","Non-GAAP net loss $(1.6)M or $(0.09) per share vs. $(0.1)M or $(0.01) last year.","Reaffirms FY2023 guidance: net revenue growth at least 10% YoY, gross margins 58-62%.","Rolling 12-month net revenue retention fell to 86% from 124%; avg revenue per top 20 pharma co. down to ~$1.99M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-038131","json":"https://secwatch.observer/filing/0001213900-23-038131.json","markdown":"https://secwatch.observer/filing/0001213900-23-038131.md","text":"https://secwatch.observer/filing/0001213900-23-038131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/0001213900-23-038131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/ea178286-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:12:00.097965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"665b3d644cc31270d2d141ca1dc72655b7bac0aa","claim":"OptimizeRx Corp reported the three months ended March 31, 2023 results: revenue $13.0 million, net income $(6.4) million, EPS $(0.37). Guidance reaffirmed.","evidence_excerpt":"Financial Highlights ● Revenue in the first quarter of 2023 decreased 5% to $13.0 million, as compared to $13.7 million in the same year ago period. ● Gross profit in the first quarter of 2023 decreased 8% year-over-year to $7.4 million, from $8.1 million during the first quarter of 2022. ● GAAP net loss totaled $(6.4) million or $(0.37) per basic and diluted shares outstanding","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/0001213900-23-038131-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$13.0 million"},{"label":"Net income","value":"$(6.4) million"},{"label":"EPS","value":"$(0.37)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}